查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1859994

无血清冷冻培养基：全球市占率及排名、总收入及需求预测（2025-2031年）

Serum-Free Freezing Media - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 124 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球无血清冷冻培养基市场规模估计为 2.43 亿美元，预计到 2031 年将达到 4.06 亿美元，在预测期（2025-2031 年）内复合年增长率为 8.1%。

本报告对近期与无血清冷冻培养基相关的关税调整和国际战略反制措施进行了全面评估，包括其对跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组的影响。

无血清冻存液是一种专门用于细胞和组织长期冷冻保存的冻存液，无需使用动物性血清（例如牛）。这类冻存液主要成分为化学成分明确的成分、重组或植物来源替代品、合成冷冻保护剂（例如DMSO或其他冷冻保护剂）、缓衝系统、渗透压调节剂和必需营养素。其目的是在超低温（通常为-80°C至液态氮）下，于储存、运输以及后续的解冻、培养/应用过程中，维持细胞的活力、形态和功能完整性。与含血清冻存液相比，无血清冻存液具有更高的批次间一致性、更低的动物性污染和病原体传播风险、更符合伦理和监管标准，并且在科研和工业生物生产环境中均具有更高的可重复性。 2024 年，全球无血清冻存液产量达到约 166,000 公升，全球平均市场价格约为每公升 1,460 美元。

随着生物製药研究、细胞和基因治疗以及再生医学在全球的快速发展，无血清冻存培养基正处于市场快速扩张阶段。首先，许多国家的管理体制正在收紧对动物性材料相关风险（病原体、交叉污染和伦理问题）的要求，迫使产业转型为无血清系统。其次，由于学术机构和工业用户都优先考虑可重复性和批间一致性，因此无血清系统可以减少血清相关的变异性，并提高解冻后细胞的活力、形态和功能完整性。第三，全球正在开发平臺的细胞疗法和疫苗数量以及投资金额都在不断增长，这要求冻存培养基必须具备卓越的安全性、稳定性和储存/运输能力。第四，新兴市场（特别是中国、印度和其他亚太国家）正在迅速加强其生物技术基础设施、研发投资和政策支持，这为无血清冻存培养基的本地化生产和市场渗透创造了巨大的机会。同时，产业内的技术创新也在加速发展。一些公司在其年度报告中表示，他们已实现了关键原材料和冷冻保护剂的内部开发，并建立了涵盖从基础研究到商业生产的一体化平台，从而降低了成本并提高了应对力（来源：公司年度报告）。

儘管存在这些重大机会，但也存在着许多挑战。首先，无血清冻存液的配方往往更为复杂，需要更高品质、更高纯度的原料以及严格的生产流程（例如，无菌、低温运输和冻融损伤控制），所有这些都会增加生产成本并降低利润率，尤其对于中小製造商而言。其次，细胞型特异性。各种细胞株（例如，干细胞、基因编辑细胞株和高密度生产细胞株）各有其独特的要求。通用的无血清冻存液可能无法为所有细胞类型提供最佳的活力和功能，因此需要耗费大量的研发週期和性能检验。第三，监理和合规风险。例如，安全认证、无残留动物成分认证、验证、批次间一致性和生物相容性都需要时间和资源。第四，竞争风险：像赛默飞世尔科技和默克这样的全球知名企业拥有强大的品牌影响力、规模和分销网络。对于新参与企业或本地企业而言，建立品牌信誉和品质口碑可能既昂贵又耗时。此外，还存在知识产权被侵犯或洩露的风险，以及由于下游客户需求变化导致配方过时的风险。

下游需求正从基础研究转向多元化和专业化。学术机构仍然是重要的需求来源，他们优先选择能够维持冷冻后细胞活力、形态和基因表现表现稳定的冻存液，以支持细胞生物学、发育生物学、免疫学和干细胞研究。製药和生物技术公司需要符合GMP或同等监管标准的冻存液，以贯穿临床前、临床和商业化阶段，并在储存和运输过程中保持良好的表现。 CDMO/CRO服务供应商正成为重要的中间用户，他们需要具有广泛适用性、品质稳定和卓越客户支援的产品，以服务其众多客户。此外，再生医学、组织工程、细胞农业和肉类替代品等新兴下游领域提出了日益严格的要求。这些要求包括高回收率、低毒性、不含动物性成分、批次间一致性高、成本效益。在成熟市场（北美和欧洲），下游需求强调合规性和高效能。与此同时，亚太地区（尤其是中国）正经历快速成长，但价格敏感度和本地供应是关键因素。中国企业（例如，亿桥神州）报告称，其无血清培养基已与多种细胞类型相容，包括HEK-293细胞和昆虫细胞，这表明市场对多种细胞类型的需求正在增长。

无血清冻存培养基的成分包括冷冻保护剂（例如二甲基亚砜、甘油、丙二醇或新型低毒替代品）、营养成分（胺基酸、维生素、无机盐、缓衝盐）、渗透压调节剂（用于控制冻融过程中的渗透压压力）、重组蛋白或生长因子或植物来源/合成替代品、无菌水、稳定剂和适当的缓衝液。其中，DMSO 或等效的保护剂仍然是主流选择，因为许多培养基仍然含有 DMSO。虽然人们对非 DMSO 替代品的兴趣日益增长，但它们在性能或市场份额方面尚未完全取代 DMSO。高纯度氨基酸、生长因子或重组蛋白价格昂贵，且供应商通常供应有限，这使得上游供应商具有优势。品质、认证（例如 GMP 或同等认证）和供应稳定性是关键的风险因素。纯度和均一性至关重要。批次/批次间的杂质和污染（化学或微生物污染）会显着降低解冻后的活性，并改变其功能特性。此外，随着全球需求的成长（尤其是在快速成长的市场），成本和前置作业时间会受到多种因素的影响，例如经认证的高纯度原材料的供应情况、物流（低温运输和运输）、进出口政策以及关税。一些公司，特别是中国的公司，在其年度报告中表示，他们正在开发或自主生产关键原材料和组件，以减少对海外供应商的依赖，控製成本并降低供应链风险。

本报告旨在按地区/国家、类型和应用对全球无血清冷冻培养基市场进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以2024年为基准年，对无血清冻存液市场规模、估算和预测进行了阐述，单位为销售量（千升）和收入（百万美元），涵盖2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并就无血清冻存液市场做出明智的商业决策。

市场区隔

公司

  • Thermo Fisher
  • Merck
  • Zenoaq
  • STEMCELL
  • Cytiva
  • BioLifeSolutions
  • Fujifilm
  • Lonza
  • Sartorius
  • Nippon Genetics
  • HiMedia
  • PromoCell

按类型分類的细分市场

  • 含有二甲基亚砜
  • 不含DMSO

应用领域

  • 学术和研究机构
  • 製药和生物技术公司

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Serum-Free Freezing Media was estimated to be worth US$ 243 million in 2024 and is forecast to a readjusted size of US$ 406 million by 2031 with a CAGR of 8.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Serum-Free Freezing Media cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Serum-Free Freezing Media refers to specialized cryopreservation media designed for long-term freezing storage of cells or tissues without using animal-derived sera (such as fetal bovine serum). Instead, these media rely on chemically defined components, recombinant or plant-derived substitutes, or synthetic cryoprotectants (e.g., DMSO or alternative cryoprotectants), buffering systems, osmotic regulators, and essential nutrients. Its purpose is to maintain cell viability, morphology, and functional integrity under ultra-low temperatures (often -80 °C down to liquid nitrogen) for storage, transport, or downstream thawing and culture/applications. Compared to serum-containing systems, serum-free freezing media offer higher batch-to-batch consistency, lower risk of animal component contamination or pathogen transmission, better alignment with ethical/regulatory standards, and improved reproducibility in both research and industrial bioproduction settings.In 2024, global Serum-Free Freezing Media production reached approximately 166 k L, with an average global market price of around US$ 1460 per L.

Against the backdrop of rapid advances in biopharmaceutical research, cell & gene therapies, and regenerative medicine globally, serum-free freezing media is at a phase of strong market expansion. First, regulatory regimes in many countries are strengthening requirements around risks associated with animal-derived materials (pathogens, cross-contamination, ethical concerns), pushing the industry to shift from serum-containing to serum-free systems. Second, both academic and industrial users are emphasizing reproducibility and batch-to-batch consistency; serum-free systems offer reduced variability introduced by serum, improving post-thaw cell viability, morphology, and functional integrity. Third, the number and investment volume of cell-based therapy/vaccine pipelines are rising worldwide; these applications demand freezing media with high safety, stability, and storage/transport performance. Fourth, emerging markets-especially in China, India, and other Asia-Pacific countries-are rapidly enhancing biotech infrastructure, R&D investment, and policy support, creating large opportunity for local manufacture and market penetration of serum-free freezing media. Meanwhile, technological innovation inside the industry is accelerating: some companies report in their annual reports that they have achieved in-house development of key raw materials or cryoprotectants and built integrated platforms spanning from basic research to commercial production, which helps lower costs and improve responsiveness. (Sources: enterprise annual reports).

Despite the strong opportunities, there are significant challenges. First, serum-free freezing media tend to have higher formulation complexity and require higher quality/purity of raw materials and stricter manufacturing processes (sterility, cold chain, control of freeze-thaw damage etc.), which all increase production cost and reduce margin, particularly for smaller manufacturers. Second, cell-type specificity: various cell lines (stem cells, gene-edited lines, high density production cell lines) each have unique requirements; a generic serum-free freezing medium may not give optimum viability/function across all, meaning long R&D cycles and performance validation are needed. Third, regulatory and compliance risks: for example, proving safety, proving residual animal-component absence, performing validation, batch consistency, biocompatibility, all take time and resources. Fourth, competitive risk: established global players like Thermo Fisher, Merck etc. have strong brand, scale, distribution; for new entrants or local firms, building brand trust, quality reputation is expensive and time consuming. There is also risk of IP infringement or leakage, or formula becoming obsolete if downstream customer needs change.

Downstream demand is trending from basic research toward greater diversity and specialization. Academic institutions remain important demand centers, prioritizing freezing media that deliver stable post-thaw viability, morphology, gene expression etc., to support cell biology, developmental biology, immunology, stem cell research. Pharma / biotech companies require freezing media that meet GMP or comparable regulatory standards across preclinical, clinical, commercial phases, and that perform well during storage/transport. CDMO / CRO service providers are becoming key mid-users, supporting many clients and needing broadly applicable, consistent quality products along with good customer support. Also, emerging downstream sectors-regenerative medicine, tissue engineering, cellular agriculture, alternative meats, etc.-are starting to specify more stringent requirements: high recovery rate, low toxicity, no animal-origin components, high batch consistency, and cost-effectiveness. Geographically, downstream demand in mature markets (North America, Europe) emphasizes compliance, premium performance; in Asia-Pacific (especially China), the growth is rapid, but price sensitivity and local supply are important factors. Chinese firms (e.g. Yiqiao Shenzhou) report that their serum-free media already cover cell types like HEK-293, insect cells etc., showing cell-type diversification of demand.

The upstream raw materials for serum-free freezing media include: cryoprotectants (e.g. DMSO, glycerol, propylene glycol or newer lower toxicity alternatives), nutritional components (amino acids, vitamins, inorganic salts, buffering salts), osmotic regulators (to manage osmotic stress during freeze/thaw), recombinant proteins or growth factors or plant/synthetic substitutes, sterile water, stabilizers and appropriate buffering agents. Among these, DMSO or equivalent protectants remain dominant because many media still include DMSO; though non-DMSO alternatives are gaining interest, they have not yet fully displaced DMSO in performance or market share. High purity amino acids, growth factors or recombinant proteins are expensive and often supplied by few vendors, giving upstream suppliers leverage and making quality, certification (e.g. GMP or equivalent), and supply stability key risks. Purity and consistency are absolutely crucial: any batch/lot impurity or contamination (chemical, microbial) can dramatically reduce post-thaw viability or alter functional behavior. Also, as demand rises globally (especially in fast-growing markets), availability of certified high-purity material, logistics (cold chain, transport), import/export policies, tariffs etc. affect cost and lead time. Some companies (notably in China) in their annual reports explicitly state that they are developing or internally producing key raw materials / componentsto reduce dependence on foreign suppliers, control cost and reduce supply chain risk.

This report aims to provide a comprehensive presentation of the global market for Serum-Free Freezing Media, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Serum-Free Freezing Media by region & country, by Type, and by Application.

The Serum-Free Freezing Media market size, estimations, and forecasts are provided in terms of sales volume (K Liters) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Serum-Free Freezing Media.

Market Segmentation

By Company

  • Thermo Fisher
  • Merck
  • Zenoaq
  • STEMCELL
  • Cytiva
  • BioLifeSolutions
  • Fujifilm
  • Lonza
  • Sartorius
  • Nippon Genetics
  • HiMedia
  • PromoCell

Segment by Type

  • With DMSO
  • DMSO-free

Segment by Application

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Serum-Free Freezing Media manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Serum-Free Freezing Media in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Serum-Free Freezing Media in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Serum-Free Freezing Media Product Introduction
  • 1.2 Global Serum-Free Freezing Media Market Size Forecast
    • 1.2.1 Global Serum-Free Freezing Media Sales Value (2020-2031)
    • 1.2.2 Global Serum-Free Freezing Media Sales Volume (2020-2031)
    • 1.2.3 Global Serum-Free Freezing Media Sales Price (2020-2031)
  • 1.3 Serum-Free Freezing Media Market Trends & Drivers
    • 1.3.1 Serum-Free Freezing Media Industry Trends
    • 1.3.2 Serum-Free Freezing Media Market Drivers & Opportunity
    • 1.3.3 Serum-Free Freezing Media Market Challenges
    • 1.3.4 Serum-Free Freezing Media Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Serum-Free Freezing Media Players Revenue Ranking (2024)
  • 2.2 Global Serum-Free Freezing Media Revenue by Company (2020-2025)
  • 2.3 Global Serum-Free Freezing Media Players Sales Volume Ranking (2024)
  • 2.4 Global Serum-Free Freezing Media Sales Volume by Company Players (2020-2025)
  • 2.5 Global Serum-Free Freezing Media Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Serum-Free Freezing Media Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Serum-Free Freezing Media Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Serum-Free Freezing Media
  • 2.9 Serum-Free Freezing Media Market Competitive Analysis
    • 2.9.1 Serum-Free Freezing Media Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Serum-Free Freezing Media Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Serum-Free Freezing Media as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 With DMSO
    • 3.1.2 DMSO-free
  • 3.2 Global Serum-Free Freezing Media Sales Value by Type
    • 3.2.1 Global Serum-Free Freezing Media Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Serum-Free Freezing Media Sales Value, by Type (2020-2031)
    • 3.2.3 Global Serum-Free Freezing Media Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Serum-Free Freezing Media Sales Volume by Type
    • 3.3.1 Global Serum-Free Freezing Media Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Serum-Free Freezing Media Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Serum-Free Freezing Media Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Serum-Free Freezing Media Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Academic & Research Institutes
    • 4.1.2 Pharmaceutical & Biotechnology Companies
  • 4.2 Global Serum-Free Freezing Media Sales Value by Application
    • 4.2.1 Global Serum-Free Freezing Media Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Serum-Free Freezing Media Sales Value, by Application (2020-2031)
    • 4.2.3 Global Serum-Free Freezing Media Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Serum-Free Freezing Media Sales Volume by Application
    • 4.3.1 Global Serum-Free Freezing Media Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Serum-Free Freezing Media Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Serum-Free Freezing Media Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Serum-Free Freezing Media Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Serum-Free Freezing Media Sales Value by Region
    • 5.1.1 Global Serum-Free Freezing Media Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Serum-Free Freezing Media Sales Value by Region (2020-2025)
    • 5.1.3 Global Serum-Free Freezing Media Sales Value by Region (2026-2031)
    • 5.1.4 Global Serum-Free Freezing Media Sales Value by Region (%), (2020-2031)
  • 5.2 Global Serum-Free Freezing Media Sales Volume by Region
    • 5.2.1 Global Serum-Free Freezing Media Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Serum-Free Freezing Media Sales Volume by Region (2020-2025)
    • 5.2.3 Global Serum-Free Freezing Media Sales Volume by Region (2026-2031)
    • 5.2.4 Global Serum-Free Freezing Media Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Serum-Free Freezing Media Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.4.2 North America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.5.2 Europe Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Serum-Free Freezing Media Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.7.2 South America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Serum-Free Freezing Media Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Serum-Free Freezing Media Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Serum-Free Freezing Media Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Serum-Free Freezing Media Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.3.2 United States Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.4.2 Europe Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.5.2 China Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.6.2 Japan Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.7.2 South Korea Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Serum-Free Freezing Media Sales Value, 2020-2031
    • 6.9.2 India Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Serum-Free Freezing Media Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Thermo Fisher
    • 7.1.1 Thermo Fisher Company Information
    • 7.1.2 Thermo Fisher Introduction and Business Overview
    • 7.1.3 Thermo Fisher Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Thermo Fisher Serum-Free Freezing Media Product Offerings
    • 7.1.5 Thermo Fisher Recent Development
  • 7.2 Merck
    • 7.2.1 Merck Company Information
    • 7.2.2 Merck Introduction and Business Overview
    • 7.2.3 Merck Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Merck Serum-Free Freezing Media Product Offerings
    • 7.2.5 Merck Recent Development
  • 7.3 Zenoaq
    • 7.3.1 Zenoaq Company Information
    • 7.3.2 Zenoaq Introduction and Business Overview
    • 7.3.3 Zenoaq Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Zenoaq Serum-Free Freezing Media Product Offerings
    • 7.3.5 Zenoaq Recent Development
  • 7.4 STEMCELL
    • 7.4.1 STEMCELL Company Information
    • 7.4.2 STEMCELL Introduction and Business Overview
    • 7.4.3 STEMCELL Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 STEMCELL Serum-Free Freezing Media Product Offerings
    • 7.4.5 STEMCELL Recent Development
  • 7.5 Cytiva
    • 7.5.1 Cytiva Company Information
    • 7.5.2 Cytiva Introduction and Business Overview
    • 7.5.3 Cytiva Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Cytiva Serum-Free Freezing Media Product Offerings
    • 7.5.5 Cytiva Recent Development
  • 7.6 BioLifeSolutions
    • 7.6.1 BioLifeSolutions Company Information
    • 7.6.2 BioLifeSolutions Introduction and Business Overview
    • 7.6.3 BioLifeSolutions Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 BioLifeSolutions Serum-Free Freezing Media Product Offerings
    • 7.6.5 BioLifeSolutions Recent Development
  • 7.7 Fujifilm
    • 7.7.1 Fujifilm Company Information
    • 7.7.2 Fujifilm Introduction and Business Overview
    • 7.7.3 Fujifilm Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Fujifilm Serum-Free Freezing Media Product Offerings
    • 7.7.5 Fujifilm Recent Development
  • 7.8 Lonza
    • 7.8.1 Lonza Company Information
    • 7.8.2 Lonza Introduction and Business Overview
    • 7.8.3 Lonza Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Lonza Serum-Free Freezing Media Product Offerings
    • 7.8.5 Lonza Recent Development
  • 7.9 Sartorius
    • 7.9.1 Sartorius Company Information
    • 7.9.2 Sartorius Introduction and Business Overview
    • 7.9.3 Sartorius Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Sartorius Serum-Free Freezing Media Product Offerings
    • 7.9.5 Sartorius Recent Development
  • 7.10 Nippon Genetics
    • 7.10.1 Nippon Genetics Company Information
    • 7.10.2 Nippon Genetics Introduction and Business Overview
    • 7.10.3 Nippon Genetics Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Nippon Genetics Serum-Free Freezing Media Product Offerings
    • 7.10.5 Nippon Genetics Recent Development
  • 7.11 HiMedia
    • 7.11.1 HiMedia Company Information
    • 7.11.2 HiMedia Introduction and Business Overview
    • 7.11.3 HiMedia Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 HiMedia Serum-Free Freezing Media Product Offerings
    • 7.11.5 HiMedia Recent Development
  • 7.12 PromoCell
    • 7.12.1 PromoCell Company Information
    • 7.12.2 PromoCell Introduction and Business Overview
    • 7.12.3 PromoCell Serum-Free Freezing Media Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 PromoCell Serum-Free Freezing Media Product Offerings
    • 7.12.5 PromoCell Recent Development

8 Industry Chain Analysis

  • 8.1 Serum-Free Freezing Media Industrial Chain
  • 8.2 Serum-Free Freezing Media Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Serum-Free Freezing Media Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Serum-Free Freezing Media Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Serum-Free Freezing Media Market Trends
  • Table 2. Serum-Free Freezing Media Market Drivers & Opportunity
  • Table 3. Serum-Free Freezing Media Market Challenges
  • Table 4. Serum-Free Freezing Media Market Restraints
  • Table 5. Global Serum-Free Freezing Media Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Serum-Free Freezing Media Revenue Market Share by Company (2020-2025)
  • Table 7. Global Serum-Free Freezing Media Sales Volume by Company (2020-2025) & (K Liters)
  • Table 8. Global Serum-Free Freezing Media Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Serum-Free Freezing Media Price by Company (2020-2025) & (USD/Liter)
  • Table 10. Key Manufacturers Serum-Free Freezing Media Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Serum-Free Freezing Media Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Serum-Free Freezing Media
  • Table 13. Global Serum-Free Freezing Media Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Serum-Free Freezing Media as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Serum-Free Freezing Media Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Serum-Free Freezing Media Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Serum-Free Freezing Media Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Serum-Free Freezing Media Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Serum-Free Freezing Media Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Serum-Free Freezing Media Sales Volume by Type: 2020 VS 2024 VS 2031 (K Liters)
  • Table 22. Global Serum-Free Freezing Media Sales Volume by Type (2020-2025) & (K Liters)
  • Table 23. Global Serum-Free Freezing Media Sales Volume by Type (2026-2031) & (K Liters)
  • Table 24. Global Serum-Free Freezing Media Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Serum-Free Freezing Media Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Serum-Free Freezing Media Price by Type (2020-2025) & (USD/Liter)
  • Table 27. Global Serum-Free Freezing Media Price by Type (2026-2031) & (USD/Liter)
  • Table 28. Global Serum-Free Freezing Media Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Serum-Free Freezing Media Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Serum-Free Freezing Media Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Serum-Free Freezing Media Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Serum-Free Freezing Media Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Serum-Free Freezing Media Sales Volume by Application: 2020 VS 2024 VS 2031 (K Liters)
  • Table 34. Global Serum-Free Freezing Media Sales Volume by Application (2020-2025) & (K Liters)
  • Table 35. Global Serum-Free Freezing Media Sales Volume by Application (2026-2031) & (K Liters)
  • Table 36. Global Serum-Free Freezing Media Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Serum-Free Freezing Media Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Serum-Free Freezing Media Price by Application (2020-2025) & (USD/Liter)
  • Table 39. Global Serum-Free Freezing Media Price by Application (2026-2031) & (USD/Liter)
  • Table 40. Global Serum-Free Freezing Media Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Serum-Free Freezing Media Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Serum-Free Freezing Media Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Serum-Free Freezing Media Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Serum-Free Freezing Media Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Serum-Free Freezing Media Sales Volume by Region (K Liters): 2020 VS 2024 VS 2031
  • Table 46. Global Serum-Free Freezing Media Sales Volume by Region (2020-2025) & (K Liters)
  • Table 47. Global Serum-Free Freezing Media Sales Volume by Region (2026-2031) & (K Liters)
  • Table 48. Global Serum-Free Freezing Media Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Serum-Free Freezing Media Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Serum-Free Freezing Media Average Price by Region (2020-2025) & (USD/Liter)
  • Table 51. Global Serum-Free Freezing Media Average Price by Region (2026-2031) & (USD/Liter)
  • Table 52. Key Countries/Regions Serum-Free Freezing Media Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Serum-Free Freezing Media Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Serum-Free Freezing Media Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Serum-Free Freezing Media Sales Volume, (2020-2025) & (K Liters)
  • Table 56. Key Countries/Regions Serum-Free Freezing Media Sales Volume, (2026-2031) & (K Liters)
  • Table 57. Thermo Fisher Company Information
  • Table 58. Thermo Fisher Introduction and Business Overview
  • Table 59. Thermo Fisher Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 60. Thermo Fisher Serum-Free Freezing Media Product Offerings
  • Table 61. Thermo Fisher Recent Development
  • Table 62. Merck Company Information
  • Table 63. Merck Introduction and Business Overview
  • Table 64. Merck Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 65. Merck Serum-Free Freezing Media Product Offerings
  • Table 66. Merck Recent Development
  • Table 67. Zenoaq Company Information
  • Table 68. Zenoaq Introduction and Business Overview
  • Table 69. Zenoaq Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 70. Zenoaq Serum-Free Freezing Media Product Offerings
  • Table 71. Zenoaq Recent Development
  • Table 72. STEMCELL Company Information
  • Table 73. STEMCELL Introduction and Business Overview
  • Table 74. STEMCELL Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 75. STEMCELL Serum-Free Freezing Media Product Offerings
  • Table 76. STEMCELL Recent Development
  • Table 77. Cytiva Company Information
  • Table 78. Cytiva Introduction and Business Overview
  • Table 79. Cytiva Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 80. Cytiva Serum-Free Freezing Media Product Offerings
  • Table 81. Cytiva Recent Development
  • Table 82. BioLifeSolutions Company Information
  • Table 83. BioLifeSolutions Introduction and Business Overview
  • Table 84. BioLifeSolutions Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 85. BioLifeSolutions Serum-Free Freezing Media Product Offerings
  • Table 86. BioLifeSolutions Recent Development
  • Table 87. Fujifilm Company Information
  • Table 88. Fujifilm Introduction and Business Overview
  • Table 89. Fujifilm Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 90. Fujifilm Serum-Free Freezing Media Product Offerings
  • Table 91. Fujifilm Recent Development
  • Table 92. Lonza Company Information
  • Table 93. Lonza Introduction and Business Overview
  • Table 94. Lonza Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 95. Lonza Serum-Free Freezing Media Product Offerings
  • Table 96. Lonza Recent Development
  • Table 97. Sartorius Company Information
  • Table 98. Sartorius Introduction and Business Overview
  • Table 99. Sartorius Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 100. Sartorius Serum-Free Freezing Media Product Offerings
  • Table 101. Sartorius Recent Development
  • Table 102. Nippon Genetics Company Information
  • Table 103. Nippon Genetics Introduction and Business Overview
  • Table 104. Nippon Genetics Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 105. Nippon Genetics Serum-Free Freezing Media Product Offerings
  • Table 106. Nippon Genetics Recent Development
  • Table 107. HiMedia Company Information
  • Table 108. HiMedia Introduction and Business Overview
  • Table 109. HiMedia Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 110. HiMedia Serum-Free Freezing Media Product Offerings
  • Table 111. HiMedia Recent Development
  • Table 112. PromoCell Company Information
  • Table 113. PromoCell Introduction and Business Overview
  • Table 114. PromoCell Serum-Free Freezing Media Sales (K Liters), Revenue (US$ Million), Price (USD/Liter) and Gross Margin (2020-2025)
  • Table 115. PromoCell Serum-Free Freezing Media Product Offerings
  • Table 116. PromoCell Recent Development
  • Table 117. Key Raw Materials Lists
  • Table 118. Raw Materials Key Suppliers Lists
  • Table 119. Serum-Free Freezing Media Downstream Customers
  • Table 120. Serum-Free Freezing Media Distributors List
  • Table 121. Research Programs/Design for This Report
  • Table 122. Key Data Information from Secondary Sources
  • Table 123. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Serum-Free Freezing Media Product Picture
  • Figure 2. Global Serum-Free Freezing Media Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Serum-Free Freezing Media Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Serum-Free Freezing Media Sales Volume (2020-2031) & (K Liters)
  • Figure 5. Global Serum-Free Freezing Media Sales Price (2020-2031) & (USD/Liter)
  • Figure 6. Serum-Free Freezing Media Report Years Considered
  • Figure 7. Global Serum-Free Freezing Media Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Serum-Free Freezing Media Players Sales Volume Ranking (2024) & (K Liters)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Serum-Free Freezing Media Revenue in 2024
  • Figure 10. Serum-Free Freezing Media Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. With DMSO Picture
  • Figure 12. DMSO-free Picture
  • Figure 13. Global Serum-Free Freezing Media Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Serum-Free Freezing Media Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Serum-Free Freezing Media Sales Volume by Type (2020 VS 2024 VS 2031) & (K Liters)
  • Figure 16. Global Serum-Free Freezing Media Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Serum-Free Freezing Media Price by Type (2020-2031) & (USD/Liter)
  • Figure 18. Product Picture of Academic & Research Institutes
  • Figure 19. Product Picture of Pharmaceutical & Biotechnology Companies
  • Figure 20. Global Serum-Free Freezing Media Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Serum-Free Freezing Media Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. Global Serum-Free Freezing Media Sales Volume by Application (2020 VS 2024 VS 2031) & (K Liters)
  • Figure 23. Global Serum-Free Freezing Media Sales Volume Market Share by Application, 2024 & 2031
  • Figure 24. Global Serum-Free Freezing Media Price by Application (2020-2031) & (USD/Liter)
  • Figure 25. North America Serum-Free Freezing Media Sales Value (2020-2031) & (US$ Million)
  • Figure 26. North America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Europe Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Europe Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Asia Pacific Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Asia Pacific Serum-Free Freezing Media Sales Value by Region (%), 2024 VS 2031
  • Figure 31. South America Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. South America Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 33. Middle East & Africa Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Middle East & Africa Serum-Free Freezing Media Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Key Countries/Regions Serum-Free Freezing Media Sales Value (%), (2020-2031)
  • Figure 36. Key Countries/Regions Serum-Free Freezing Media Sales Volume (%), (2020-2031)
  • Figure 37. United States Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. United States Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 39. United States Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Europe Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Europe Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Europe Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 43. China Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. China Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 45. China Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Japan Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Japan Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Japan Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 49. South Korea Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. South Korea Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 51. South Korea Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Southeast Asia Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 53. Southeast Asia Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 54. Southeast Asia Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 55. India Serum-Free Freezing Media Sales Value, (2020-2031) & (US$ Million)
  • Figure 56. India Serum-Free Freezing Media Sales Value by Type (%), 2024 VS 2031
  • Figure 57. India Serum-Free Freezing Media Sales Value by Application (%), 2024 VS 2031
  • Figure 58. Serum-Free Freezing Media Industrial Chain
  • Figure 59. Serum-Free Freezing Media Manufacturing Cost Structure
  • Figure 60. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 61. Bottom-up and Top-down Approaches for This Report
  • Figure 62. Data Triangulation
  • Figure 63. Key Executives Interviewed